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Pulmonary epithelioid hemangioendothelioma (PEH) is a rare neoplasm of vascular origin.There are three differentmajor imaging
patterns identified in thoracic manifestation of epithelioid hemangioendothelioma: (1) multiple pulmonary nodules; (2) multiple
pulmonary reticulonodular opacities; and (3) diffuse infiltrative pleural thickening. Radiographically, presence of bilateral multiple
nodules is themost commonpattern of presentation.Thediagnosis ismade on the basis of histopathological findings and confirmed
by positive immunohistochemistry staining. Although the prognostic factors for PEH have not yet been well established, a better
prognosis is usually associatedwith themultinodular pattern.We report twodifferent imagological presentations of this rare disease,
based on two institutional experiences, along with a review of the relevant literature.
1. Introduction
Pulmonary epithelioid hemangioendothelioma (PEH) is a
rare neoplasm of vascular origin. It is a low-to-intermediate
grade malignant tumor, of borderline malignancy and a
clinical course usually between hemangioma and angiosar-
coma. Unfortunately, there is no clear definition of malignant
PEH.The term “epithelioid hemangioendothelioma” was first
introduced by Weiss et al. as a soft tissue vascular tumor of
borderline malignancy [1].
However, the lesion was originally described in 1975 by
Dail et al. as an “intravascular bronchoalveolar tumor,” ini-
tially believed to be an aggressive formof the bronchoalveolar
cell carcinoma [2].
Epithelioid hemangioendothelioma (EH) is classified as
a vascular tumor because the neoplastic cells have charac-
teristics in common with normal, nonneoplastic endothelial
cells [3]. EH can behave in a locally aggressive fashion, with
metastases being rare [4].
Corrin et al., using immunohistochemical techniques,
demonstrated the presence of malignant cells deriving
from a lineage capable of differentiation along endothelial
lines [5]. Subsequently, Weldon-Linne et al., using electron
microscopy, confirmed these results and revealed diffuse
cytoplasmic staining of the tumor cells with a factor VIII-
related antigen [6].
Histologic characteristics of EH include epithelioid cells
with abundant eosinophilic cytoplasm in a fibromyxoid
stroma, some of themwith intracytoplasmic vacuoles, having
a signet ring-like appearance. These features can, however,
be also found in primary adenocarcinoma, mesothelioma,
and large-cell lymphoma, so immunohistochemical analyses,
especially those for the endothelial markers, are a mainstay
[7–10].
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Figure 1: Posteroanterior (a) and lateral (b) chest X-rays. The chest radiography showed a diffuse nodular pulmonary pattern in both lungs.
The 2015 WHO Classification of Tumors of the Lung,
Pleura, Thymus and Heart [11] recently published, with
numerous important changes from the 2004 WHO clas-
sification, has a significant change involving recognition
of usefulness of WWTR1-CAMTA1 fusions in diagnosis of
pulmonary EH. The new information regarding this tumor
is recognition of a translocation involving the WWTR1 and
CAMTA1 genes and prognostic factors [12].
This update was based on the recent recognition that
a recurrent t(1;3)(p36.3;q25) chromosomal translocation is
characteristic of EH. Additionally, the genes involved in the
EH translocation were identified, namely, WWTR1 (or TAZ)
and CAMTA1, resulting in a transcription factor, WWTR1-
CAMTA1 fusion protein. Also significant is the lack of
CAMTA1 andWWTR1 rearrangements in epithelioid heman-
gioma, a benign vascular tumor that can be misdiagnosed as
EH [13–17].
Tanas et al. [18] suggest that the WWTR1/CAMTA1 gene
fusion plays a pivot role in the tumor biology and can act
as a transcription factor that ultimately may represent a
therapeutic target for EH-specific drugs. Recently, Antonescu
et al. [19, 20] report a novel subset of EH occurring in a
specific group of young adults, where they found a distinct
phenotype with YAP1-TFE3 fusions but similar morphologic
features. Although further studies [21] confirm these results
others question the utility of immunohistochemical YAP1-
TFE3 fusion detection [7, 14].
Another hypothesis for the pathogenesis of this neo-
plasm, reported in the literature, mentions a possible causal
relationship between chronic Bartonella infection and the
development of this rare vascular tumor in immunocompe-
tent patients [22].
Some authors also believe in a hormonal potential sig-
nificance in this disease because the greater incidence is
observed in women; also, hormone receptor expression has
been reported in the literature [23, 24] and a recent case
report describes recurrence of EH during pregnancy [25].
All these data highlight the current emerging devel-
opment about the knowledge concerning biochemical and
clinical behaviour of EH in general and PEH in particular and
can lead to greater understanding of the molecular pathways
in the tumor and great advances in potential therapies.
EH remains, however, a little-understood disease and one
of the main reasons for that is the fact that the prevalence of
EH is reported to be less than one in 1 million [26].
2. Case 1
A 35-year-old male, nonsmoker, without symptoms and
with no prior history of lung diseases had a routine chest
radiograph that showed alterations. His past medical history
was not significant, without occupational exposures or family
history of clinical relevance. The physical examination was
unremarkable. Chest X-ray demonstrated the presence of a
diffuse and bilateral micronodular infiltrate (Figure 1).
Serum levels of neoplastic markers and angiotensin con-
verting enzyme were within normal values. The pulmonary
function tests were also in the normal range. The bron-
choscopy performed with bronchoalveolar lavage, brushing,
and transbronchial biopsies were nondiagnostic. Chest high
resolution (HR) computed tomography (CT) scan showed
multiple, bilateral small pulmonary nodules (with diameters
inferior to 10mm) (Figure 2).
These nodules were present in all pulmonary lobes and
adjacent to bronchioles and medium/small vessels. There
were no enlarged lymph nodes, pleural effusion, or other
relevant pulmonary changes. Abdominal and pelvic CT
revealed no malignant lesions (Figure 3).
Radiological skeletal study also showed no bone involve-
ment. Surgical lung biopsy was performed and histological
examination of the nodules revealed epithelioid cells with
eosinophilic cytoplasm and intracytoplasmic vacuolization.
On immunohistochemical studies, the tumor cells were
immunoreactive to CD34 and negative for cytokeratin (Fig-
ure 4).
Because the progression was slow, follow-up was sug-
gested. In agreement with his decision, close follow-up with
chest CT was planned.
He still has no symptoms and has survived for 48 months
following the initial diagnosis.
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Figure 2: Chest CT (a and b). Multislice chest CT-images on lung window showed innumerable, well-defined, small, round, and noncalcified




Figure 3: Contrast-enhanced multislice CT of the chest (a) on mediastinal window showed no thoracic lymphadenopathy. Multislice
abdominopelvic CT scans (b and c) with intravenous contrast administration showed no significant findings, excluding focal liver or splenic
lesions.
3. Case 2
A 67-year-old woman, nonsmoker, presented in the emer-
gency department with a complaint ofmild productive cough
for 2 months with hematic sputum in the last 24 hours.
She also reported progressive left-sided dorsal pain over 1-
month duration. Her pastmedical history revealed a previous
diagnosis of deep vein thrombosis in 2012. In a routine chest
radiograph made 2 years previously, it was hard to depict any
pulmonary pathology (Figure 5).
Her family history was unremarkable. There were no
other specific abnormalities on physical examination. The
laboratory findings were within normal range. Chest X-ray
demonstrated the presence of a poorly defined opacity in the
left lower lung and a blunt costophrenic angle in the left side
(Figure 6).
Spirometry showed forced vital capacity (FVC) of 1.59
(69.1%), forced expiratory volume in 1 second (FEV1) of 1.16
(60.7%), FEV1/FVC of 76%, and diffusing capacity divided
by the alveolar volume (DLCO/VA) of 103.3%. Extensive
pulmonary workup for pulmonary nodules including bron-
choscopy, bronchoalveolar lavage (BAL), and transbronchial
lung biopsy was completed. Results were negative for infec-
tious or rheumatologic processes. The transbronchial biopsy
4 Case Reports in Radiology
(a) (b)
(c) (d)
Figure 4: Histopathologic findings of hemangioendothelioma. (a) Low magnification of the specimen obtained from pulmonary wedge
resection reveals a subpleural nodule that extends to adjacent alveoli, with vascular proliferation in the peripheral zone and areas of recent
and old hemorrhage. (b) Neoplastic nodule showing tumor cells with an eosinophilic stroma at the periphery.The lesion contains blood filled
spaces and respiratory epithelium “trapped” within the lesion is also shown. (c) Higher magnification of the tumor reveals vacuolation of
some of the tumor cells, representing primitive angiogenesis. One of these epithelioid cells can be observed with intracytoplasmic lumen
and an erythrocyte inside, indicating their vascular nature. (d) Immunostaining for CD34 revealed positivity of the neoplastic cells (brown
colour), confirming the endothelial lineage of the tumor.
(a) (b)
Figure 5: Posteroanterior (a) and lateral (b) chest X-rays. In a routine chest radiography 2 years before presentation in the ER it was difficult
to detect the lesion in the left lower lung.
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Figure 6: Posteroanterior (a) and lateral (b) chest X-rays.The chest radiography showed a peripheral lesion in the left lower lung and a small
volume of pleural effusion on the same side.
(a) (b)
Figure 7: Transbronchial biopsy of a pulmonary mass (H-E). (a) 10x. (b) 20x. Vascular proliferation and endothelial cells, frequently with
citoplasmatic vacuolization, in a fibromyxoid stroma, with bronchial surface epithelial lining.
showed atypical cellular infiltrate with immunohistochemical
expression very suggestive of proliferative lesion of vascular
origin (Figure 7).
A chest CT scan revealed the presence of a lung mass in
the parenchyma of the left inferior lobe (LIL), with necrotic
component and in contact with the parietal pleura and
diaphragmatic pleura, with associated partial atelectasis of
the same lobe and coexisting multiple nodules scattered in
both lungs (Figure 8); a single hilar ipsilateral lymphadenopa-
thy was identified and no mediastinal lymphadenopathy or
significant pleural effusion were present at presentation.
Patient underwent a first chest CT-guided lung biopsy
that revealed intense fibrosis and focal changes suggestive of
proliferative vascular lesion. She repeated the lung biopsy that
showed the presence of atypical epithelioid-like tumor cells
(Figure 9). Immunohistochemical studies were positive for
CD31, CD34, and factor VIII. These results were consistent
with the diagnosis of PEH.
She underwent a FDG PET/CT (not shown) that showed
areas of increased uptake of FDG, including the pulmonary
mass in the LIL as a hypermetabolic lesion and the left hilar
lymphadenopathy.Therewas no abnormal FDGuptake in the
small pulmonary nodules
One thoracic magnetic resonance (MR) with paramag-
netic contrast, done two months later, demonstrated a left
pleural effusion but did not show unequivocal abnormal
pleural enhancement compatible with pleural metastases
(Figure 10).
Three months later, under general anaesthesia, the sur-
geons performed a wedge resection by thoracotomy that
also revealed multiple small pleural implants, both in vis-
ceral and in parietal pleural lesions, which were biopsied.
Tumor specimens acquired showed pathological features
of EH.
After a scheduled oncology visit the patient began treat-
ment with six cycles of chemotherapy with carboplatin/
paclitaxel,which changed to doxorubicin/cyclophosphamide.
Another chest CT, three months after the initial CT,
showed rapid progression of the disease depicted by increase
in number of the pulmonary nodules and the pleural lesions.
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Figure 8: Chest CT.Multislice chest CT-images on lung window (a, b, and c) showed a lungmass with irregular borders (a); they also showed
multiple small, round, and noncalcified pulmonary nodular opacities, scattered in both lungs (b and c). On mediastinal window (d, e, and f)
it is possible to better identify the pleural invasion (d) and the necrotic areas in lesion (e), retrospectively, and valorization is hard when the
exam was performed, and we can recognize areas of enhancement in the left pleura, more nodular (arrow) or linear (arrowhead) (f).
Also, showing increment in diameter, the splenic nodular
lesions were compatible with metastases (Figure 11).
The patient returned to emergency department, seven
months after the first visit, with progressive dyspnea.
A chest CT made at this time showed advance disease
with a new lesion appearing in the contralateral pulmonary
parenchymal and growth of the primary lesion in the left
lung, illustrating the aggressive behaviour of the disease.
The pulmonary nodules, however, did not show significant
increment in size despite the completely different evolution
seen in the lesion of the lower left lung (Figure 12).
Unlike this, the spleen showed an increase in number and
size of the nodular lesions in his parenchyma. Although we
did not have pathologic confirmation, because the patient did
not have any other primary neoplastic lesion, these features
reinforce the probable diagnosis of metastases from the PEH
(Figure 13).
Upon her readmission, 2 weeks later, the patient suc-
cumbed to her condition due to respiratory failure.
4. Discussion
Using the International Hemangioendothioma, Epithelioid
Hemangioendothelioma, and Related Vascular Disorders
(HEARD) Registry, an Internet database with data of 206
patients, Lau et al. [15] found that the most commonly
affected organs were liver and lung, and single organ involve-
ment occurred in more than 60% of patients. The most
common presentations were liver alone (21%), liver plus lung
(18%), lung alone (12%), and bone alone (14%).
There is still no characteristic clinical or biologicalmarker
for PEH. PEH typically occurs among young patients and is
more common in women than in men and many patients
are asymptomatic at presentation, so it is often an incidental
finding on imaging studies. Other possible symptoms can be
minor or nonspecific pulmonary symptoms, such as chest
pain, effort dyspnea, cough, and sputum [8, 14, 26–32]. There
are sporadic reported cases of atypical symptoms related to
unusual clinical course and/or extraordinary aggressiveness
[33].
The prognosis is very variable, with survival ranging from
less than one year up to 30 years [34]. Slow progression or
growth for long periods and spontaneous regression may
occur, especially in asymptomatic patients [27]. According to
Lau et al. analysis, the 5-year overall survival is 73% [15]. The
mortality for lung disease, with a minimum of follow-up of 4
years, was reported to be 65% [1].
The prognostic factors for PEH have not yet been well
established. Pulmonary symptoms and, specially, pleural
hemorrhagic effusions and hemoptysis are generally consid-
ered the worst prognostic factors [28]. Symptomatic patients
and presence of pleural effusion were found to be indepen-
dent predictors of survival. Other significant risk factors for
PEH are male gender, presence of cough, chest pain, multiple
unilateral nodules, metastases to more than one site, and
lymph node metastases [26].




Figure 9: 20G Tru-Cut biopsy of the lung mass (a). H-E (b–e) images show vascular proliferation with epithelioid cells in a fibromyxoid
stroma and presence of haemosiderophages ((b, c) 10x; (d) 20x). Some of the epithelioid cells show vacuolation (e). Immunostaining for
CD31 revealed positivity of the neoplastic cells (brown colour), confirming the endothelial lineage of the tumor.
Another study using cases from International HEARD
Support Group found that although concurrent multiorgan
involvement is common at the time of diagnosis, no specific
organ or combination of organ involvement differentially
affected survival, and there were no differences in patient’s
survival with single versus multiple organ involvement in
their cohort [15]. They also confirmed that hemoptysis and
pleural effusion or other signs of uncontained tumor growth
have prognostic value and involve worse survival. These
authors also categorized the patients into two different pat-
terns of disease at presentation (A and B) based on presence
or absence of lesions with discrete/defined borders, with
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Figure 10: Thoracic MR images. Fluid sensitive sequences (a–c) show the presence of left pleural effusion (arrowhead) and also the nodular
lesions in the spleen, which do not correspond to cysts (arrows). T1 weighted images with contrast (d and e) show the pulmonary mass and
hypodense zones representing necrotic areas (arrow).
pattern B in the chest including pulmonary infiltrates, pleural
effusion, extrapulmonary thoracic disease, and the symptom
of hemoptysis and found a strong predictive prognostic value.
In terms of clinical features, it seems that the prognosis of
PHE reflects primarily the vascular aggressivenessmarkers of
hemorrhagic symptoms.
Although there are controversies regarding the multicen-
tric or metastatic nature of EH, it can affect many organs
simultaneously or sequentially, and lungs and liver are the
two organs most frequently involved [15, 30, 35]. Although
PEH is capable of producing regional and distant metastases,
the metastases occur less frequently than in conventional
angiosarcoma [26].
Dissemination of PEH can occur through blood vessels
and lymphatics and within the pleural cavity [36]. Although
rare, when the primary location is the lungs, distant metas-
tases to the liver, skin, kidney, spleen, and retroperitoneum
can occur and have been reported in the literature [2, 27, 28,
37–41]. Weiss et al. [1] reported that metastatic disease occurs
in approximately 15% of patients with lesions affecting the
lung.
Although it is unclear if the expression of CD44 has a
major role in PEH invasiveness and metastases (because the
number of patients tested is limited) Yi et al. [42] suggested
the potential of intravascular invasion in a patient presenting
with pulmonary thromboembolic disease and pulmonary
hypertension.
Nevertheless, in patients with also hepatic involvement,
knowledge of the CT manifestations in the liver may be
helpful to narrow the differential diagnoses.
EH in the thorax can involve not just the lungs but also the
pleurae and the mediastinum [14, 31, 43–45]. There are three
major different patterns of CT findings identified in thoracic
manifestation of EH [46–48]: (1) multiple pulmonary nod-
ules; (2) multiple pulmonary reticulonodular opacities; and
(3) diffuse infiltrative pleural thickening.
Radiographically, bilateral multiple nodular nodules are
the most common presentation [27, 49]. The presence of
multiple discrete pulmonary perivascular nodules with well-
or ill-defined margins in both lungs on chest radiographs
or CT is the characteristic finding. The nodules can range
in size up to 3 cm, but most are less than 1 cm in diameter
and are usually found in relation to small and medium-
sized vessels and bronchi. This form of presentation may
appear in many lung diseases and is easily mistaken for
metastatic carcinoma, which is usually the initial radiologic
interpretation [50]. However, little growth is shown on
serial chest CT examinations [8, 50]. When this pattern
is found the differential diagnosis list generally includes
the following: pulmonary metastases, miliary granulomatous
infection, sarcoidosis, silicosis, primary lungmalignancy, and
lymphangitic carcinomatosis.
There is a trend toward better prognosis for the multin-
odular pattern and the largest studies/reviews that assess
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Figure 11: Chest CT. Multislice chest axial CT-images on mediastinal window show (a) signs of previous atypical wedge resection in the left
lower lobe (arrow); (b) more nodular lesions in the spleen (arrows); (c and d) more pronounced and diffuse pleural invasion (brackets).
the relation between imaging features/different patterns and
prognosis show that longer survival corresponds to the
presence of multiple pulmonary nodules [26–28, 30, 32].
To the best of our knowledge, at least when the imaging
pattern was specifically reported, all the cases that report
complete/partial response or with spontaneous regression
correspond to the multinodular pattern [1, 27, 34, 37, 51–61]
This issue is extremely important because, due to the
heterogeneity of PEH, the specific imaging pattern from
radiologic diagnosis may be a pivot step in the approach of
the patient with PEH and ultimately can define the option
about the treatment. Furthermore, perhaps the results about
treatment efficacy cannot be compared when the lesions do
not have homogeneous patterns.
Particularly interesting is the fact already described in
other tumors not so distinct from PEH, like is the case
of bronchioloalveolar carcinoma. In these tumors it is the
clinical pattern and pathologic stage, and not the degree of
invasion on histologic examination, that can predict survival
[62].
Multiple pulmonary reticulonodular opacities represent,
histopathologically, areas of infiltrating nodular proliferation
of neoplastic cells within the lumina of small blood vessels
and lymphatic vessels [26, 29, 47, 49]. In fact, in their
study, Woo et al. [32] found a clinical significance in their
similarity to pulmonary metastases in terms of prognosis,
although just three patients had this pattern. This pattern
may also suggest amore aggressive infiltrative growth into the
lung interstitium, depicted histopathologically by infiltrative
nodular proliferation of tumor cells within the vessel lumina
[63, 64].
When the disease presents as diffuse infiltrative pleural
thickening with associated pleural effusion, it can simulate
malignant pleural mesothelioma or diffuse pleural carcino-
matosis [16, 45, 65, 66].
An extra pattern can be added to the previous three
identified ones, defined as parenchymal tumor with pleural
invasion [32]. This pattern was previously described in some
reports in the literature [27, 67–70] and Woo et al. described
it in 4 patients.Themajor importance of this pattern relies on
the fact that imaging features can greatly simulate the much
more common primary non-small-cell lung tumor. Indeed,
as was the case with all the four patients of Woo et al. study,
also in one of our patients primary lung cancer with pleural
seeding was the initial differential diagnosis.
Other unusual radiologic findings in sporadic cases are
described in the literature, like irregular interstitial thick-
ening and ground-glass opacities as the dominant feature,
mimicking diffuse lung disease [63].




Figure 12: Chest CT. Multislice chest axial CT-images on mediastinal window (a, b, and c) show increase in size of the main lesion (a) and
pleural metastases in the left side (arrows) and in contralateral side (arrowhead); a new lesion in the right lung is observed (arrow in (c)).
Multislice chest axial CT-images on lung window (d and e) show the new contralateral lesion (arrow in (d)) and the parenchymal pulmonary
nodules did not vary significantly in size from the previous studies (arrows in (e)).
(a) (b)
Figure 13: Multislice chest CT. Axial images on mediastinal window at the pulmonary bases (a and b) show increase in size and number of
the nodular spleen lesions (arrows). A pleural effusion in the right side is also apparent (arrowhead).
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Although histologic calcifications are common, radio-
logic visible calcifications are rare. In long-standing cases or
after treatment, extensive calcification of the nodules can be
seen [67, 71].
PET/CT findings can demonstrate increased FDG-
uptakes but usually are not a pivotal tool for the diagnosis,
and a negative PET cannot exclude PEH [72, 73]. This false
negative result is thought to be caused because of the small
size of nodules, little FDG activity in the neoplasm, or low
cellular density. Conversely, other studies show that FDG
uptake may reflect the activation of PEH tumor cells, which
is a sign of a poorer prognosis [74, 75]. One particular study
demonstrated the PET/CT scan utility to differentiate PEH
from amyloidosis in a patient with both conditions [73].Most
patients who underwent PET/CT in the study by Woo et al.
[32] showed increased FDGuptake at the corresponding lung
lesions on CT.
The most problematic pattern, undoubtedly, is the
multinodular pattern where the lung nodules were 20mm
or less in diameter, decreasing the diagnostic accuracy and
reliability of PET-CT.
Due to its rarity and heterogeneousmode of presentation,
diagnosis of PEH can be really defiant. The diagnosis usually
requires a lung biopsy, and histopathological samples are
usually obtained from open-lung or thoracoscopic biopsy.
Chest CT-guided lung biopsy can also be an option due
to potential increased risk of bleeding associated with this
vascular-like tumor or when the lesion is peripheral. A
few reports report diagnosis made through bronchoscopy
biopsies [8, 71, 76]. Fine needle aspiration can produce
erroneous results [77].
The diagnosis ismade on the basis of these histopatholog-
ical features and confirmed by positive immunohistochem-
istry staining for vascular-endothelial markers, like CD31,
CD34, and factor VIII [46].
Some histologic findings, like spindle tumor cells and
fibrinous pleuritic lesion with extrapleural tumor cells prolif-
eration, are linked to aworse prognosis [27, 28, 78]. Regarding
correlation between the histopathological findings and prog-
nosis Kitaichi et al. [27] found that fibrinofibrous pleuritic
lesions with extrapleural proliferation of tumor cells and
the presence of spindle tumor cells were the characteristics
associated with worse prognosis. Interestingly, intravascular
invasion and invasion of the visceral pleura by tumor cells
without fibrinous pleuritis were observed in the two patients
with spontaneous partial regression in their study.
In a more recent study, Anderson et al. [14], in 39
cases of EH with thoracic involvement, found that higher
tumor grade and the presence of pleural involvement in
lung and/or pleural tumors correlate with poor prognosis.
They suggest that the reported criteria for classifying and
grading malignant vascular tumors within soft tissue might
be applicable to tumors in the thoracic cavity, including PEH.
There is no established standard treatment consensus
for therapeutic regimens available, particularly owing to its
borderline malignancy features and scarcity of cases [30,
79]. Spontaneous partial regressions are reported, particu-
larly in asymptomatic patients, as we already reported [27].
Radiotherapy has proven to be ineffective for PEH because
of the tumor’s radiobiological characteristics, particularly
the slow growth of tumor cells [37]. Surgery when tumor
resection is feasible is usually considered the treatment of
choice [80, 81]. However, a complete surgical resection is
usually not feasible. Chemotherapy/immunostimulants in
patients with disseminated disease and lung transplantation
can also be an option [28, 58, 59, 61, 81–85]. Although there
are a small number of reports about the effectiveness of
chemotherapy, a general standard of chemotherapy is usually
accepted for PEH [8]. Pinet et al. [82] reported a case of an
aggressive formof pleural EH resulting in complete remission
after treatment with carboplatin plus etoposide. Given the
vascular origin of this tumor, the use of antiangiogenetic
drugs reasonably might achieve good outcomes, including
thalidomide, lenalidomide, and bevacizumab [61, 79, 84–86].
Ye et al. [58], in their review concerning chemotherapy and
immunotherapy used in PEH, demonstrated a good partial
response to chemotherapy with carboplatin, paclitaxel, beva-
cizumab, thalidomide, and 𝛼-interferon. In their study, these
authors also described three patients with stabilization of
the disease and a dramatic improvement in clinical status
when treated with a combination regimen that included
Endostar or bevacizumab. This was the first report of
the efficacy of Endostar, a recently introduced recombinant
human endostatin, considered to be a valuable antiangiogenic
agent. However, no change in the size of the pulmonary
nodules over the period of chemotherapy was observed and
treatment was unable to stop the progression of disease.
Further studies of treatment are warranted to provide a better
knowledge for different combination chemotherapies options
to treat PEH.
Regular follow-up with no active therapy has been
employed in asymptomatic patients, specifically in cases with
diffuse lesions corresponding to multinodular pattern [2, 74,
87].
5. Conclusions
These two cases emphasise the large spectrum of presenta-
tion, clinical behaviour, and outcome of PHE.
Further investigations are essential to elucidate the pro-
gression of the disease and therapeutic options for patients
with PEH.
Particularly, different imaging patterns of PHE need
to be correlated with the recent molecular/genetic features
identified, in order to confirm their prognostic value.
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